logo-loader

Blackrock Gold unveils new high-grade gold and silver intercepts from the DPB target at Tonopah West project

Published: 10:20 03 Dec 2020 EST

Blackrock Gold Corp -
Blackrock has initiated a resource definition program on the target with the goal of delivering an initial resource by the end of 2021

Blackrock Gold Corp (CVE:BRC) (OTCMKTS:BKRRF) has revealed more high-grade gold and silver intercepts from a highly prospective target on its Tonopah West project in Nevada.

Drilling on the Denver, Paymaster and Bermuda (DPB) target returned three metres at 10.5 grams per ton (g/t) gold and 1,188 g/t silver (2,238 g/t silver equivalent) along the Merton vein, which Blackrock said indicates 290 metres of dip potential.

Other holes returned 12.2 metres at 297 g/t silver equivalent at the Bermuda-Merton vein intersection and 4.5 metres grading 285 g/t silver equivalent on the Paymaster vein.

READ: Blackrock Gold continues to hit "phenomenal grades" at its Tonopah West project in Nevada

Drilling defined mineralization over 300 metres along Paymaster, Blackrock told investors. All DPB veins are open to the east and west as well as up and down dip, the group added.

Vancouver-based Blackrock has initiated a resource definition program on the DPB target with the goal of delivering an initial resource by the end of 2021.

Blackrock CEO Andrew Pollard told shareholders that the zone is “starting to take shape” thanks to the additional high-grade results that highlight the potential for a significant resource.

"Drilling continues to confirm our geologic model, and as we're now establishing continuity and mineralization of the many tightly-spaced veins in this corridor, all of which remain open, we're putting together an extremely aggressive plan that will see us fast-track to deliver an initial resource estimate before the end of 2021,” Pollard said in a statement.

“This is a transformational step for any project, and moving from a maiden round of drilling to resource delineation mode so quickly underscores the calibre of this target, providing investors with something compelling to look forward to over the next twelve months.”

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

8 hours, 51 minutes ago